Medication info
Danggijanucombi Tablet 50/1000 mg

Danggijanucombi Tablet 50/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride with Colloidal Anhydrous Silica›1010mg / 1 tablet
Manufacturer / importer
Myeongmoon Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
30 tablets/box[(10 tablets/PTP x 3)]
Approval status
Active

MFDS item code 202200406 · Approved 2022.01.24 · Insurance code 649807970

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for patients who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient’s current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should take the patient’s blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Ingredients

Manufacturer
Myeongmoon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty in blood sugar control
View approved original text

This drug is used in conjunction with dietary management and exercise therapy to assist in blood sugar control for patients with type 2 diabetes. It may be administered to individuals who have no prior experience with diabetes medication or in cases where monotherapy is insufficient for blood sugar control. Additionally, it can be used when monotherapy with metformin or sitagliptin is inadequate or to replace a combination therapy with both drugs. When used in conjunction with metformin, sulfonylureas, thiazolidinediones, or insulin, it can also improve blood sugar control when these medications alone are insufficient. It thus aids in managing diabetes by enhancing blood sugar control in a variety of therapeutic settings.

How to take

Adult dose

The dose of this medicine for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for patients who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient’s current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should take the patient’s blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Precautions

This medication is a diabetes treatment that contains both sitagliptin and metformin. First, this drug can cause rare but serious allergic reactions, so if symptoms such as skin rash, hives, or difficulty breathing occur, stop taking it immediately and consult a physician. Moreover, there may be an inflammation of the pancreas known as pancreatitis, so if symptoms such as abdominal pain, nausea, or vomiting arise, you must seek medical attention right away. This drug should not be administered to patients with compromised kidney function, acute heart failure, myocardial infarction, or severe infections. Especially in cases of decreased kidney function, the ingredients of this drug can accumulate in the body, potentially leading to a dangerous condition known as lactic acidosis, so regular kidney function tests should be performed, and the medication should be discontinued if necessary. Lactic acidosis can present with symptoms such as muscle pain, weakness, difficulty breathing, and abdominal pain, so if these symptoms occur, you must immediately inform medical personnel. Avoid excessive alcohol consumption while taking this medication, and temporarily stop the medication during surgery, severe dehydration, or infection. Also, symptoms of hypoglycemia may occur, so do not skip meals, take the medication regularly, and exercise caution as the risk of hypoglycemia may increase when used in conjunction with other blood glucose-lowering agents. It is advisable for pregnant or breastfeeding women not to use this drug, and safety has not been established for children and adolescents under 18 years old. Finally, while taking this medication, regular kidney function and blood tests should be conducted to check for abnormalities, and if any unusual symptoms arise during treatment, consult a doctor immediately.

Side effects

Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, peripheral edema, severe and disability-associated arthralgia, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, dermatitis, anorexia, weight loss, neutrophilia, elevated liver enzymes, acute renal failure, decreased appetite, itching, dizziness, dyspnea, unstable angina, dizziness, abdominal pain, dizziness, acute renal failure, hypoglycemic symptoms, reduced serum vitamin B12, anemia, vesicles, maceration

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air and preferably kept at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness and prevent deterioration.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

30 tablets/box[(10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.